Published peptide research references
Retatrutide
Governed registry record
25 approved source records with original-source links. Source verification confirms the reference and its connection to this record; it does not certify every scientific conclusion or establish safety or efficacy.
Open the peptide evidence profile →Approved source records
Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial.
Harpreet S Bajaj, Michelle Welch, Parag Shah, Eduardo Luna, Fatima-Zahra Jaouimaa, Bing Liu, Rong Liu, Yanyun Chen · 2026
Retatrutide in type 2 diabetes mellitus and obesity: an overview.
Theodoros Panou, Evanthia Gouveri, Djordje S Popovic, Nikolaos Papanas · 2026
The Triple-Agonist Revolution: Retatrutide and the Paradigm Shift in Multi-Hormonal Pharmacotherapy for Obesity and Cardiometabolic Comorbidities.
Nila Ganamurali, Sarvesh Sabarathinam · 2026
Appetite, eating attitudes, and eating behaviours during treatment with retatrutide in adults with type 2 diabetes: Results of a phase 2 study.
Chisom Kanu, Kristina S Boye, Jiat Ling Poon, Iris Goetz, Suzanne Williamson, Jitong Lou, Mark L Hartman, Corby K Martin · 2025
Decreases in circulating ANGPTL3/8 concentrations following retatrutide treatment parallel reductions in serum lipids.
Yi Wen, Deven Lemen, Yanzhu Lin, Yan Q Chen, Ajit Regmi, William C Roell, Melissa K Thomas, Mark L Hartman · 2025
Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial.
Tamer Coskun, Qiwei Wu, Nanette C Schloot, Axel Haupt, Zvonko Milicevic, Courtney Khouli, Charles Harris · 2025
Efficacy and Safety of GLP-1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian NMA.
Binayak Sinha, Samit Ghosal · 2025
Efficacy and Safety of Retatrutide in the Treatment of Diabetes and/or Obesity Comorbid with Chronic Kidney disease: a Systematic Review and Meta-Analysis.
Kumari Pallavi, Anshuman Chandra, Keshav Kumar, Kumar Martand, Shyam Sundar Sahu, Lalit Mohan, Anita Verma · 2025
Efficacy and safety of retatrutide for the treatment of obesity: a systematic review of clinical trials.
Saurav Misra, Ravi Kant Narayan, Manmeet Kaur · 2025
Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials.
Alaa Abdrabou Abouelmagd, Amro Mamdouh Abdelrehim, Mohamed Nabih Bashir, Fares Abdelsalam, Ahmed Marey, Yousef Tanas, Duha Milad Abuklish, Mohamed Mohamed Belal · 2025
Efficacy and safety of triple hormone receptor agonist retatrutide for the management of obesity: a systematic review and meta-analysis.
Jay Tewari, Khalid Ahmad Qidwai, Ajoy Tewari, Savneet Kaur, Vineeta Tewari, Anuj Maheshwari · 2025
Efficacy of Tirzepatide, Retatrutide, and Semaglutide for Weight Loss in Obese Individuals Without Diabetes.
Bastu Adebayo Olowo-Oribi, Richard James Salway · 2025
Emerging pharmacotherapies for obesity: A systematic review.
Michail Kokkorakis et al. · 2025
Retatrutide-A Game Changer in Obesity Pharmacotherapy.
Vasiliki Katsi, Georgios Koutsopoulos, Christos Fragoulis, Kyriakos Dimitriadis, Konstantinos Tsioufis · 2025
The promise of glucagon-like peptide 1 receptor agonists (GLP-1RA) for the treatment of obesity: a look at phase 2 and 3 pipelines.
Sten Madsbad, Jens J Holst · 2025
A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity.
Manmeet Kaur, Saurav Misra · 2024
Comparative Meta-Analysis of Retatrutide Versus Placebo and Dulaglutide for Weight Loss and Diabetes Management: Insights From Clinical Trials.
Hazem Ayesh, Suhail Ayesh, Kevin Niswender · 2024
Effect of retatrutide on liver fat content in adults with metabolic dysfunction-associated steatotic liver disease: a substudy of a randomised, double-blind, placebo-controlled, phase 2 trial
2024
Effects of once-weekly subcutaneous retatrutide on weight and metabolic markers: A systematic review and meta-analysis of randomized controlled trials.
Eric Pasqualotto, Rafael Oliva Morgado Ferreira, Matheus Pedrotti Chavez, Alexandre Hohl, Marcelo Fernando Ronsoni, Tales Pasqualotto, Francisco Cezar Aquino de Moraes, Larissa Hespanhol · 2024
Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity.
Daniel J Drucker · 2024
The power of three: Retatrutide's role in modern obesity and diabetes therapy.
Toufik Abdul-Rahman, Poulami Roy, Fatma Kamal Ahmed, Jann Ludwig Mueller-Gomez, Sarmistha Sarkar, Neil Garg, Victor Oluwafemi Femi-Lawal, Andrew Awuah Wireko · 2024
Retatrutide showing promise in obesity (and type 2 diabetes).
Sheila A Doggrell · 2023
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
2023
Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
2023
LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept
2022